Meeder Asset Management’s Niagen Bioscience NAGE Stock Holding History

Meeder Asset Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-826	Closed	-$7.71K	–	1010
2025 Q3	$7.71K	Hold	826	–	–	﹤0.01%	593
2025 Q2	$11.9K	Buy	+826	New	+$8.16K	﹤0.01%	585
2018 Q3	–	Sell	-1,495	Closed	-$5.55K	–	1715
2018 Q2	$5.55K	Buy	+1,495	New	+$5.68K	﹤0.01%	1254
2018 Q1	–	Sell	-252	Closed	-$1K	–	1777
2017 Q4	$1K	Sell	252 -425	-63%	-$2.29K	﹤0.01%	1604
2017 Q3	$3K	Buy	677 +31	+5%	+$113	﹤0.01%	1390
2017 Q2	$2K	Sell	646 -105	-14%	-$333	﹤0.01%	1437
2017 Q1	$2K	Hold	751	–	–	﹤0.01%	1418
2016 Q4	$2K	Buy	+751	New	+$2.04K	﹤0.01%	939

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Meeder Asset Management's NAGE Position: Q4 2025 in Review

Meeder Asset Management sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 826 shares — an estimated $7.71K sold.

Meeder Asset Management first reported a position in NAGE in Q4 2016 and held it in 8 quarters. The position peaked at $11.9K in Q2 2025. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

Meeder Asset Management reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
Meeder Asset Management sold 826 Niagen Bioscience shares in Q4 2025, an estimated $7.71K.
Meeder Asset Management first reported a position in Niagen Bioscience in Q4 2016 and held it in 8 quarters.
Meeder Asset Management's Niagen Bioscience position peaked at $11.9K in Q2 2025.
169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on Meeder Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.